Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 143.5 Million EUR | 964.46% |
| 2022 | -16.6 Million EUR | 64.76% |
| 2021 | -47.1 Million EUR | -3523.08% |
| 2020 | -1.3 Million EUR | -8.33% |
| 2019 | -1.2 Million EUR | -111.32% |
| 2018 | 10.6 Million EUR | 213.98% |
| 2017 | -9.3 Million EUR | -114.55% |
| 2016 | 63.9 Million EUR | 189.0% |
| 2015 | -71.8 Million EUR | -234.46% |
| 2014 | 53.4 Million EUR | -0.74% |
| 2013 | 53.8 Million EUR | 20.48% |
| 2012 | 44.65 Million EUR | 7.44% |
| 2011 | 41.56 Million EUR | -3.11% |
| 2010 | 42.89 Million EUR | -30.22% |
| 2009 | 61.47 Million EUR | 10.49% |
| 2008 | 55.63 Million EUR | 44.47% |
| 2007 | 38.51 Million EUR | 22.7% |
| 2006 | 31.38 Million EUR | 24.14% |
| 2005 | 25.28 Million EUR | 35.73% |
| 2004 | 18.62 Million EUR | 143.41% |
| 2003 | 7.65 Million EUR | 12.78% |
| 2002 | 6.78 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 25.6 Million EUR | -51.52% |
| 2024 Q1 | 52.8 Million EUR | 191.71% |
| 2023 Q3 | 133.3 Million EUR | 361.25% |
| 2023 Q4 | 18.1 Million EUR | -86.42% |
| 2023 Q2 | 28.9 Million EUR | 417.58% |
| 2023 Q1 | -9.1 Million EUR | -479.17% |
| 2023 FY | 143.5 Million EUR | 964.46% |
| 2022 Q3 | -9.9 Million EUR | -135.71% |
| 2022 Q4 | 2.4 Million EUR | 124.24% |
| 2022 FY | -16.6 Million EUR | 64.76% |
| 2022 Q1 | -5 Million EUR | 86.07% |
| 2022 Q2 | -4.2 Million EUR | 16.0% |
| 2021 Q4 | -35.9 Million EUR | -1280.77% |
| 2021 Q1 | -9.3 Million EUR | -243.08% |
| 2021 Q2 | 800 Thousand EUR | 108.6% |
| 2021 Q3 | -2.6 Million EUR | -425.0% |
| 2021 FY | -47.1 Million EUR | -3523.08% |
| 2020 FY | -1.3 Million EUR | -8.33% |
| 2020 Q1 | 1.4 Million EUR | -80.0% |
| 2020 Q2 | -700 Thousand EUR | -150.0% |
| 2020 Q3 | -8.5 Million EUR | -1114.29% |
| 2020 Q4 | 6.5 Million EUR | 176.47% |
| 2019 FY | -1.2 Million EUR | -111.32% |
| 2019 Q4 | 7 Million EUR | 359.26% |
| 2019 Q3 | -2.7 Million EUR | -161.36% |
| 2019 Q2 | 4.4 Million EUR | 144.44% |
| 2019 Q1 | -9.9 Million EUR | -280.0% |
| 2018 FY | 10.6 Million EUR | 213.98% |
| 2018 Q4 | 5.5 Million EUR | 25.0% |
| 2018 Q3 | 4.4 Million EUR | 22.22% |
| 2018 Q2 | 3.6 Million EUR | 220.0% |
| 2018 Q1 | -3 Million EUR | -146.88% |
| 2017 FY | -9.3 Million EUR | -114.55% |
| 2017 Q4 | 6.4 Million EUR | 42.22% |
| 2017 Q3 | 4.5 Million EUR | -4.26% |
| 2017 Q2 | 4.7 Million EUR | 118.88% |
| 2017 Q1 | -24.9 Million EUR | -165.87% |
| 2016 Q2 | 9.6 Million EUR | 11.63% |
| 2016 Q4 | 37.8 Million EUR | 378.48% |
| 2016 Q3 | 7.9 Million EUR | -17.71% |
| 2016 FY | 63.9 Million EUR | 189.0% |
| 2016 Q1 | 8.6 Million EUR | -15.69% |
| 2015 Q3 | -84.3 Million EUR | -3931.82% |
| 2015 Q2 | 2.2 Million EUR | 2100.0% |
| 2015 Q1 | 100 Thousand EUR | -99.45% |
| 2015 FY | -71.8 Million EUR | -234.46% |
| 2015 Q4 | 10.2 Million EUR | 112.1% |
| 2014 FY | 53.4 Million EUR | -0.74% |
| 2014 Q3 | 8.8 Million EUR | -44.3% |
| 2014 Q4 | 18.1 Million EUR | 105.68% |
| 2014 Q2 | 15.8 Million EUR | 47.66% |
| 2014 Q1 | 10.7 Million EUR | -23.02% |
| 2013 Q4 | 13.9 Million EUR | -0.71% |
| 2013 FY | 53.8 Million EUR | 20.48% |
| 2013 Q2 | 14.1 Million EUR | 19.49% |
| 2013 Q1 | 11.8 Million EUR | -0.45% |
| 2013 Q3 | 14 Million EUR | -0.71% |
| 2012 FY | 44.65 Million EUR | 7.44% |
| 2012 Q2 | 12.5 Million EUR | 20.19% |
| 2012 Q3 | 9.9 Million EUR | -20.8% |
| 2012 Q4 | 11.85 Million EUR | 19.73% |
| 2012 Q1 | 10.4 Million EUR | -9.25% |
| 2011 Q2 | 10.9 Million EUR | 19.78% |
| 2011 Q4 | 11.46 Million EUR | 13.47% |
| 2011 Q3 | 10.1 Million EUR | -7.34% |
| 2011 FY | 41.56 Million EUR | -3.11% |
| 2011 Q1 | 9.1 Million EUR | 18.27% |
| 2010 Q1 | 12.3 Million EUR | -13.22% |
| 2010 Q4 | 7.69 Million EUR | -33.1% |
| 2010 Q2 | 11.4 Million EUR | -7.32% |
| 2010 FY | 42.89 Million EUR | -30.22% |
| 2010 Q3 | 11.5 Million EUR | 0.88% |
| 2009 FY | 61.47 Million EUR | 10.49% |
| 2009 Q4 | 14.17 Million EUR | -11.97% |
| 2009 Q3 | 16.1 Million EUR | -0.62% |
| 2009 Q2 | 16.2 Million EUR | 8.0% |
| 2009 Q1 | 15 Million EUR | 0.0% |
| 2008 FY | 55.63 Million EUR | 44.47% |
| 2007 FY | 38.51 Million EUR | 22.7% |
| 2006 FY | 31.38 Million EUR | 24.14% |
| 2005 FY | 25.28 Million EUR | 35.73% |
| 2004 FY | 18.62 Million EUR | 143.41% |
| 2003 FY | 7.65 Million EUR | 12.78% |
| 2002 FY | 6.78 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Qrons Inc. | -643.67 Thousand USD | 22393.79% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -75.317% |
| Nascent Biotech, Inc. | -2.22 Million USD | 6535.327% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1004.237% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 11525.159% |
| BioStem Technologies, Inc. | -7.77 Million USD | 1944.717% |
| CSL Limited | 3.7 Billion USD | 96.124% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 2944.692% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 904.057% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 358.521% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 20989.439% |
| Skye Bioscience, Inc. | -13.67 Million USD | 1149.606% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 34638.448% |
| Rebus Holdings, Inc. | -664 Thousand USD | 21711.446% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 10845.594% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 36935.485% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 299.9% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2819.746% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 54928.332% |
| SQZ Biotechnologies Company | -75.82 Million USD | 289.252% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 5134.192% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 9442.15% |
| Mesoblast Limited | -84.14 Million USD | 270.535% |
| Marizyme, Inc. | -34.08 Million USD | 520.988% |
| Genus plc | 6.4 Million USD | -2142.188% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -1372.934% |
| Pharming Group N.V. | -4.87 Million USD | 3040.849% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 7323.837% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 15507.245% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 1818.563% |
| ContraFect Corporation | -56.88 Million USD | 352.246% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 3250.574% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 10335.444% |
| IMV Inc. | -38.67 Million USD | 471.074% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 5316.59% |
| MultiCell Technologies, Inc. | -722.81 USD | 19853173.422% |
| ONE Bio Corp. | 13.68 Million USD | -948.858% |
| Accustem Sciences Inc. | -3.74 Million USD | 3930.324% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 343.262% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 29806.332% |
| Q BioMed Inc. | -3.44 Million USD | 4264.712% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -3953.672% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 5561.42% |
| Biomind Labs Inc. | -1 Million USD | 14313.508% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 361.04% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 5046.144% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 2258.539% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 7796.97% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 479199.893% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 7525.192% |
| GB Sciences, Inc. | -1.42 Million USD | 10202.013% |
| Alpha Cognition Inc. | -9.7 Million USD | 1578.528% |
| HST Global, Inc. | -140.9 Thousand USD | 101940.221% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 12856.621% |
| Halberd Corporation | -75.05 Thousand USD | 191305.863% |
| Enzolytics Inc. | -2.14 Million USD | 6778.146% |
| Agentix Corp. | -1.37 Million USD | 10561.044% |
| Resverlogix Corp. | -12.74 Million USD | 1225.578% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 4629.28% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 133.761% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 13845.211% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 5015.319% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 9185.988% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 4314.417% |
| AVAX Technologies, Inc. | 6.69 Million USD | -2044.07% |
| Zenith Capital Corp. | -8.94 Million USD | 1704.607% |
| Genscript Biotech Corporation | -415.79 Million USD | 134.513% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 823818.501% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 5944.459% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 83768.815% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 7257.975% |
| Kadimastem Ltd | -3.04 Million USD | 4820.007% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 14682.548% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 79169.896% |
| LadRx Corporation | -3.82 Million USD | 3852.982% |
| Cell Source, Inc. | -4.32 Million USD | 3417.654% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 20989.439% |
| NovAccess Global Inc. | -2.46 Million USD | 5917.347% |
| Affymax, Inc. | -15.04 Million USD | 1053.742% |
| Itoco Inc. | -919.14 Thousand USD | 15712.42% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 3485.7% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 12923.95% |
| Mobile Lads Corp. | -554.55 Thousand USD | 25976.837% |
| CytoDyn Inc. | -18.05 Million USD | 894.662% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 570223.162% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 65304.155% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 25510.688% |
| SYBLEU INC | -149.18 Thousand USD | 96292.519% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 8000.59% |
| International Stem Cell Corporation | -663 Thousand USD | 21744.042% |
| Bioxytran, Inc. | -3.82 Million USD | 3856.4% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 272706.383% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 705606.391% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 495.687% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 8968.974% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 19601.655% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 4712.665% |
| Neutra Corp. | -229.48 Thousand USD | 62631.048% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 918.177% |
| PureTech Health plc | -146.19 Million USD | 198.154% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 767.718% |
| IXICO plc | -1.43 Million USD | 10086.082% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 1611.959% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 217.81% |
| CSL Limited | 3.81 Billion USD | 96.236% |
| Cellectis S.A. | -108.85 Million USD | 231.824% |